Sort by
Refine Your Search
-
Listed
-
Country
-
Employer
- THE UNIVERSITY OF HONG KONG
- University of North Carolina at Chapel Hill
- CNRS
- Duke University
- King's College London
- Stanford University
- University of Maryland, Baltimore
- University of Oslo
- FAPESP - São Paulo Research Foundation
- HONG KONG BAPTIST UNIVERSITY
- Institut Pasteur
- Institute of Physical Chemistry, Polish Academy of Sciences
- SUNY University at Buffalo
- Saint Louis University
- University of California, Los Angeles
- University of Oxford
- University of Washington
- Yale University
- Aarhus University
- Baylor College of Medicine
- CIC bioGUNE
- Columbia Center for Translational Immunoogy
- Delaware State University
- EPFL
- Eli Lilly and Company
- Imperial College London
- Indiana University
- Institute of Macromolecular Chemistry CAS
- Iowa State University
- Johns Hopkins University
- Lunds universitet
- Rutgers University
- SciLifeLab
- St Jude Children's Research Hospital
- Texas A&M AgriLife
- The Ohio State University
- Umeå University
- Uniklinik Köln
- University of Colorado
- University of Copenhagen
- University of Lund
- University of Oxford;
- University of Texas at Dallas
- Wroclaw University of Science and Technology
- Zintellect
- 35 more »
- « less
-
Field
-
, No UMO-2020/39/I/NZ5/03104, Dissecting cancer activome to develop new generation of antibody-drug conjugates, PI: PhD. Eng. DSc. Marcin Poręba, professor at WUST Type of position: research assistant
-
releasing growth factors, chemotherapeutics and antibodies. These systems will be tested in vitro in a traditional 2D setting or, newly, in a semi-perfusion 3D system with preformed vasculature and
-
companies and actors from the healthcare sector. A number of important infrastructures are available, including specialized laboratories for antibody development, flow cytometry, spatial omics, and mass
-
University of North Carolina at Chapel Hill | Chapel Hill, North Carolina | United States | 10 days ago
will lead research on developing automated, high throughput organ-on-chip platforms for evaluation of antibody therapeutic pharmacokinetics and safety. Fundamental to this work, the fellow will be
-
University of North Carolina at Chapel Hill | Chapel Hill, North Carolina | United States | about 4 hours ago
will lead research on developing automated, high throughput organ-on-chip platforms for evaluation of antibody therapeutic pharmacokinetics and safety. Fundamental to this work, the fellow will be
-
of the current laboratory studies. The selected candidate is expected to work on existing projects in nanomedicines and drug delivery, as well as to develop new directions, such as antibody drug conjugates
-
replication timing drives the biogenesis of tumorigenic chromosomal translocations. Our lab studies the molecular mechanisms by which somatic hypermutation generates protective antibodies against pathogen and
-
of resistance to targeting therapies (antibodies, and antibody-drug conjugates) integrating clinical data, 3D cancer cell models, high-throughput approaches and co-culture systems. The successful candidate will
-
: Experience with electrochemical techniques applied to the characterization of interfaces and charge-transfer processes; nanostructured materials and thin films; surface functionalization and aptamer, antibody
-
, including specialized laboratories for antibody development, flow cytometry, spatial omics, and mass spectrometry, as well as NBIS (National Bioinformatics Infrastructure Sweden). The Department is also